Caceres BA, Jackman KB, Edmondson D, Bockting WO. Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014–2017 BRFSS. J Behav Med. 2020;43(2):329–38. https://doi.org/10.1007/s10865-019-00102-8.
Winter S, Diamond M, Green J, Karasic D, Reed T, Whittle S, et al. Transgender people: health at the margins of society. Lancet. 2016;388(10042):390–400. https://doi.org/10.1016/S0140-6736(16)00683-8.
Grant JM, Mottet L, Tanis JE, Herman J, Harrison J, Keisling M, et al. National transgender discrimination survey report on health and health care: findings of a study by the National Center for Transgender Equality and the National Gay and Lesbian Task Force. National Center for Transgender Equality; 2010. https://cancer-network.org/wp-content/uploads/2017/02/National_Transgender_Discrimination_Survey_Report_on_health_and_health_care.pdf. Accessed 1 June 2022.
• Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, Decuypere G, Feldman J, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2011;13(165). https://www.wpath.org/publications/soc. Accessed 1 June 2022. This paper provides comprehensive clinical guidelines and expert consensus for the safe and effective care of transgender and gender diverse persons. An updated version 8 is expected to be published in 2022.
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017. https://doi.org/10.1210/jc.2017-01658.
Deutsch MB. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people introduction to the guidelines. San Francisco, CA. 2016. https://transcare.ucsf.edu/sites/transcare.ucsf.edu/files/Transgender-PGACG-6-17-16.pdf. Accessed 1 June 2022.
Edmiston EK, Donald CA, Sattler AR, Peebles JK, Ehrenfeld JM, Eckstrand KL. Opportunities and gaps in primary care preventative health services for transgender patients: a systemic review. Transgend Health. 2016;1(1):216–30. https://doi.org/10.1089/trgh.2016.0019.
Article PubMed PubMed Central Google Scholar
• Caceres BA, Streed CG, Jr., Corliss HL, Lloyd-Jones DM, Matthews PA, Mukherjee M, et al. Assessing and addressing cardiovascular health in LGBTQ adults: a scientific statement from the American Heart Association. Circulation. 2020;142(19):e321-e32. https://doi.org/10.1161/CIR.0000000000000914. This scientific statement presents a comprehensive review of available evidence and conceptual models on the cardiovascular health of transgender, gender diverse, and sexual minority adults.
Lewis T, Williams D, Tamene M, Clark C. Self-reported experiences of discrimination and cardiovascular disease. Curr Cardiovasc Risk Rep. 2014;8:365.
Panza GA, Puhl RM, Taylor BA, Zaleski AL, Livingston J, Pescatello LS. Links between discrimination and cardiovascular health among socially stigmatized groups: a systematic review. PLoS ONE. 2019;14(6):e0217623.
Project. MA: Equality maps: state nondiscrimination laws. https://www.lgbtmap.org/equality-maps/non_discrimination_laws/public-accommodations Accessed 02/15/2022.
Casey LS, Reisner SL, Findling MG, Blendon RJ, Benson JM, Sayde JM, et al. Discrimination in the United States: experiences of lesbian, gay, bisexual, transgender, and queer Americans. Health Serv Res. 2019;54(Suppl 2):1454–66. https://doi.org/10.1111/1475-6773.13229.
Article PubMed PubMed Central Google Scholar
Lagos D, Compton D. Evaluating the use of a two-step gender identity measure in the 2018 general social survey. Demography. 2021;58(2):763–71. https://doi.org/10.1215/00703370-8976151.
Lombardi E, Banik S. The utility of the two-step gender measure within trans and cis populations. Sex Res Social Policy. 2016;13(3):288–96. https://doi.org/10.1007/s13178-016-0220-6.
Article PubMed PubMed Central Google Scholar
Asscheman H, Giltay EJ, Megens JAJ, De Ronde W, Van Trotsenburg MAA, Gooren LJG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164(4):635–42. https://doi.org/10.1530/EJE-10-1038.
CAS Article PubMed Google Scholar
Van Kesteren PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol. 1997;47(3):337–43. https://doi.org/10.1046/j.1365-2265.1997.2601068.x.
Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Ø. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J. 2008;29(21):2660–8. https://doi.org/10.1093/EURHEARTJ/EHN408.
Renoux C, Dell’Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340(7763):83. https://doi.org/10.1136/BMJ.C2519.
Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428–32. https://doi.org/10.1016/S0140-6736(03)14066-4.
CAS Article PubMed Google Scholar
Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost. 2007;97(4):558–65.
Lacut K, Oger E, Le Gal G, Blouch MT, Abgrall JF, Kerlan V, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost. 2003;90(1):124–31.
Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab. 2008;93(5):1702–10. https://doi.org/10.1210/jc.2007-2193.
CAS Article PubMed Google Scholar
Nii S, Shinohara K, Matsushita H, Noguchi Y, Watanabe K, Wakatsuki A. Hepatic effects of estrogen on plasma distribution of small dense low-density lipoprotein and free radical production in postmenopausal women. J Atheroscler Thromb. 2016;23(7):810–8. https://doi.org/10.5551/jat.33175.
CAS Article PubMed PubMed Central Google Scholar
Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93(1):19–25. https://doi.org/10.1210/JC.2007-1809.
CAS Article PubMed Google Scholar
Prior JC, Vigna YM, Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav. 1989;18(1):49–57. https://doi.org/10.1007/BF01579291.
CAS Article PubMed Google Scholar
Oriel KA. Clinical update: medical care of transsexual patients. J Gay Lesbian Med Assoc. 2000;4:185–94.
Prior JC. Progesterone is important for transgender women’s therapy—applying evidence for the benefits of progesterone in ciswomen. J Clin Endocrinol Metab. 2019;104(4):1181–6. https://doi.org/10.1210/jc.2018-01777.
Prior JC, Seifert-Klauss VR, Giustini D, Adachi JD, Kalyan S, Goshtasebi A. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy—a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact. 2017;17(3):146–54.
CAS PubMed PubMed Central Google Scholar
Manson JAE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2013;310(13):1353–68. https://doi.org/10.1001/jama.2013.278040.
CAS Article PubMed Google Scholar
Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–5. https://doi.org/10.1161/CIRCULATIONAHA.106.642280.
CAS Article PubMed Google Scholar
Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34(2):171–208. https://doi.org/10.1210/er.2012-1008.
CAS Article PubMed Google Scholar
Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation. 2008;118(8):863–71. https://doi.org/10.1161/CIRCULATIONAHA.107.760405.
Nagai M, Forster CY, Dote K. Sex hormone-specific neuroanatomy of Takotsubo syndrome: is the insular cortex a moderator? Biomolecules. 2022;12(1). https://doi.org/10.3390/biom12010110.
Dart AM, Du XJ, Kingwell BA. Gender, sex hormones and autonomic nervous control of the cardiovascular system. Cardiovasc Res. 2002;53(3):678–87. https://doi.org/10.1016/s0008-6363(01)00508-9.
CAS Article PubMed Google Scholar
Alzahrani T, Nguyen T, Ryan A, Dwairy A, McCaffrey J, Yunus R, et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes. 2019;12(4):e005597. https://doi.org/10.1161/CIRCOUTCOMES.119.005597.
Nota NM, Wiepjes CM, de Blok CJM, Gooren LJG, Kreukels BPC, den Heijer M. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation. 2019;139(11):1461–2. https://doi.org/10.1161/CIRCULATIONAHA.118.038584.
Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med. 2018;169(4):205–13. https://doi.org/10.7326/M17-2785.
Article PubMed PubMed Central Google Scholar
Stone T, Stachenfeld NS. Pathophysiological effects of androgens on the female vascular system. Biol Sex Differ. 2020;11(1):45. https://doi.org/10.1186/s13293-020-00323-6.
Article PubMed PubMed Central Google Scholar
Gulanski BI, Flannery CA, Peter PR, Leone CA, Stachenfeld NS. Compromised endothelial function in transgender men taking testosterone. Clin Endocrinol (Oxf). 2020;92(2):138–44. https://doi.org/10.1111/cen.14132.
van Velzen DM, Paldino A, Klaver M, Nota NM, Defreyne J, Hovingh GK, et al. Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen. J Clin Endocrinol Metab. 2019;104(6):1937–47. https://doi.org/10.1210/jc.2018-02138.
Banks K, Kyinn M, Leemaqz SY, Sarkodie E, Goldstein D, Irwig MS. Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults. Hypertension. 2021;77(6):2066–74. https://doi.org/10.1161/HYPERTENSIONAHA.120.16839.
CAS Article PubMed Google Scholar
Colizzi M, Costa R, Scaramuzzi F, Palumbo C, Tyropani M, Pace V, et al. Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: a 2 year follow-up study. J Psychosom Res. 2015;78(4):399–406. https://doi.org/10.1016/J.JPSYCHORES.2015.02.001.
留言 (0)